# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Ross Osborn maintains Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $17 ...
HC Wainwright & Co. analyst Edward White reiterates Nyxoah (NASDAQ:NYXH) with a Buy and maintains $18 price target.
Oppenheimer analyst Suraj Kalia maintains Nyxoah (NASDAQ:NYXH) with a Outperform and lowers the price target from $15 to $13.
Nyxoah (NASDAQ:NYXH) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.40) by 1...
"Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of in...
Stifel analyst Jonathan Block maintains Nyxoah (NASDAQ:NYXH) with a Buy and lowers the price target from $27 to $19.
Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialization and commercialization activitie...
HC Wainwright & Co. analyst Edward White maintains Nyxoah (NASDAQ:NYXH) with a Buy and lowers the price target from $22 ...